Therapy Areas: Infectious Diseases
Motif Bio to present new iclaprim data at ECCMID 2018
19 April 2018 - Motif Bio (LON: MTFB) will present new clinical and pre-clinical data for its investigational drug candidate iclaprim at the 28th European Congress of Clinical Microbiology and Infecti...
Mobidiag Launches Diagnostic Test for on-Demand Detection of Bacterial Pathogens
19 April 2018 - - Espoo, Finland-based molecular diagnostics company Mobidiag has launched Novodiag Bacterial GE+, a molecular diagnostic test for the simultaneous detection of most common enteric pat...
Alnylam Study of Givosiran for Treatment of Acute Hepatic Porphyrias Demonstrates Lowering of Urinary ALA and Decrease in Porphyria Attack Rate
18 April 2018 - - Cambridge, Massachusetts-based RNA interference therapeutics developer Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) has presented new results from the Phase 1 and Phase 1/2 open-labe...
Morphotek Licenses Proprietary Eribulin-Linker Payload to Bliss Biopharmaceutical for Development of Therapeutic ADC
16 April 2018 - - Exton, Pennsylvania-based clinical-stage biotechnology company Morphotek, Inc. has licensed its eribulin-linker payload to Hangzhou, China-based biopharmaceutical company Bliss Bioph...
Morphotek Licenses Proprietary Eribulin-Linker Payload to Bliss Biopharmaceutical for Development of Therapeutic ADC
12 April 2018 - - Exton, Pennsylvania-based clinical-stage biotechnology company Morphotek, Inc. has licensed its eribulin-linker payload to Hangzhou, China-based biopharmaceutical company Bliss Bioph...
Final Analysis of Mologen IMPULSE Study Confirms Topline Data with Positive Subgroup Results
10 April 2018 - - Berlin, Germany-based biopharmaceutical company Mologen AG's final evaluation of the randomized exploratory phase II IMPULSE study confirmed findings presented in April 2017 and...